Investor Roadmap

QUIA – NZI Ltd will go public through a Reverse Takeover (RTO) on the London Stock Exchange Main Market by late 2025 or early 2026.

We are also evaluating a future listing on the New York Stock Exchange (NYSE), following our strategic alignment with BIO VITOS PHARMA.

Why Invest in QUIA – NZI?

  • Clinically validated product pipeline
  • Two high-growth market segments: iron deficiency & obesity
  • High-margin, subscription-based model
  • LSE and potentially NYSE exposure
  • Scalable global impact

 Iron Deficiency (Men)

  • 2.5 billion men aged 18–70 globally
  • ~17,5% affected = 325+ million potential users
  • Revenue at 1M users/year: £240M
  • Gross profit/year: £216M

Obesity (Men & Women)

  • 650M+ adults obese (WHO)

  • 1B+ overweight

  • Revenue at 5M users/year: £2.4B

  • Gross profit/year: ~£2.1B

QUIA – NZI is well-positioned to scale both products with high adoption potential and substantial margin profiles.

Clinical Roadmap

MAX I FER I MAN Study

  • Start Date: September 2025
  • Supervised by: Professor Fredrik Nyström
  • Modeled after: FEMININ Study by BIO VITOS PHARMA
  • Expected Completion: December 2025

Obesity Patch Clinical Testing

  • Pre-clinical data ongoing
  • Pilot study planned for 2026
  • Focused on safety, effectiveness, and regulatory compliance for EU and U.S. markets.

Support Your Body’s Needs Daily

Our carefully formulated supplements provide essential nutrients that help manage iron deficiency and support healthy metabolism. Take control of your well-being with a simple daily routine designed for long-term results.

Clinically Backed and Trusted

Developed in collaboration with medical professionals, our solutions are pain-free, discreet, and supported by scientific research. Whether you’re tackling obesity, iron imbalance, or both, we offer tools you can trust.